Worsening of chronic heart failure : definition, epidemiology, management and prevention. A clinical consensus statement by the Heart Failure Association of the European Society of Cardiology
© 2023 European Society of Cardiology..
Episodes of worsening symptoms and signs characterize the clinical course of patients with chronic heart failure (HF). These events are associated with poorer quality of life, increased risks of hospitalization and death and are a major burden on healthcare resources. They usually require diuretic therapy, either administered intravenously or by escalation of oral doses or with combinations of different diuretic classes. Additional treatments may also have a major role, including initiation of guideline-recommended medical therapy (GRMT). Hospital admission is often necessary but treatment in the emergency service or in outpatient clinics or by primary care physicians has become increasingly used. Prevention of first and recurring episodes of worsening HF is an essential component of HF treatment and this may be achieved through early and rapid administration of GRMT. The aim of the present clinical consensus statement by the Heart Failure Association of the European Society of Cardiology is to provide an update on the definition, clinical characteristics, management and prevention of worsening HF in clinical practice.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:25 |
|---|---|
| Enthalten in: |
European journal of heart failure - 25(2023), 6 vom: 19. Juni, Seite 776-791 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 12.07.2023 Date Revised 18.07.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/ejhf.2874 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM357114426 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM357114426 | ||
| 003 | DE-627 | ||
| 005 | 20231226071907.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/ejhf.2874 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1190.xml |
| 035 | |a (DE-627)NLM357114426 | ||
| 035 | |a (NLM)37208936 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Metra, Marco |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Worsening of chronic heart failure |b definition, epidemiology, management and prevention. A clinical consensus statement by the Heart Failure Association of the European Society of Cardiology |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 12.07.2023 | ||
| 500 | |a Date Revised 18.07.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 European Society of Cardiology. | ||
| 520 | |a Episodes of worsening symptoms and signs characterize the clinical course of patients with chronic heart failure (HF). These events are associated with poorer quality of life, increased risks of hospitalization and death and are a major burden on healthcare resources. They usually require diuretic therapy, either administered intravenously or by escalation of oral doses or with combinations of different diuretic classes. Additional treatments may also have a major role, including initiation of guideline-recommended medical therapy (GRMT). Hospital admission is often necessary but treatment in the emergency service or in outpatient clinics or by primary care physicians has become increasingly used. Prevention of first and recurring episodes of worsening HF is an essential component of HF treatment and this may be achieved through early and rapid administration of GRMT. The aim of the present clinical consensus statement by the Heart Failure Association of the European Society of Cardiology is to provide an update on the definition, clinical characteristics, management and prevention of worsening HF in clinical practice | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Emergency department visits | |
| 650 | 4 | |a Hospitalization | |
| 650 | 4 | |a Intensification of oral therapy | |
| 650 | 4 | |a Outpatients | |
| 650 | 4 | |a Prognosis | |
| 650 | 4 | |a Worsening heart failure | |
| 650 | 7 | |a Angiotensin-Converting Enzyme Inhibitors |2 NLM | |
| 650 | 7 | |a Adrenergic beta-Antagonists |2 NLM | |
| 650 | 7 | |a Diuretics |2 NLM | |
| 700 | 1 | |a Tomasoni, Daniela |e verfasserin |4 aut | |
| 700 | 1 | |a Adamo, Marianna |e verfasserin |4 aut | |
| 700 | 1 | |a Bayes-Genis, Antoni |e verfasserin |4 aut | |
| 700 | 1 | |a Filippatos, Gerasimos |e verfasserin |4 aut | |
| 700 | 1 | |a Abdelhamid, Magdy |e verfasserin |4 aut | |
| 700 | 1 | |a Adamopoulos, Stamatis |e verfasserin |4 aut | |
| 700 | 1 | |a Anker, Stefan D |e verfasserin |4 aut | |
| 700 | 1 | |a Antohi, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Böhm, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Braunschweig, Frieder |e verfasserin |4 aut | |
| 700 | 1 | |a Gal, Tuvia Ben |e verfasserin |4 aut | |
| 700 | 1 | |a Butler, Javed |e verfasserin |4 aut | |
| 700 | 1 | |a Cleland, John G F |e verfasserin |4 aut | |
| 700 | 1 | |a Cohen-Solal, Alain |e verfasserin |4 aut | |
| 700 | 1 | |a Damman, Kevin |e verfasserin |4 aut | |
| 700 | 1 | |a Gustafsson, Finn |e verfasserin |4 aut | |
| 700 | 1 | |a Hill, Loreena |e verfasserin |4 aut | |
| 700 | 1 | |a Jankowska, Ewa A |e verfasserin |4 aut | |
| 700 | 1 | |a Lainscak, Mitja |e verfasserin |4 aut | |
| 700 | 1 | |a Lund, Lars H |e verfasserin |4 aut | |
| 700 | 1 | |a McDonagh, Theresa |e verfasserin |4 aut | |
| 700 | 1 | |a Mebazaa, Alexandre |e verfasserin |4 aut | |
| 700 | 1 | |a Moura, Brenda |e verfasserin |4 aut | |
| 700 | 1 | |a Mullens, Wilfried |e verfasserin |4 aut | |
| 700 | 1 | |a Piepoli, Massimo |e verfasserin |4 aut | |
| 700 | 1 | |a Ponikowski, Piotr |e verfasserin |4 aut | |
| 700 | 1 | |a Rakisheva, Amina |e verfasserin |4 aut | |
| 700 | 1 | |a Ristic, Arsen |e verfasserin |4 aut | |
| 700 | 1 | |a Savarese, Gianluigi |e verfasserin |4 aut | |
| 700 | 1 | |a Seferovic, Petar |e verfasserin |4 aut | |
| 700 | 1 | |a Sharma, Rajan |e verfasserin |4 aut | |
| 700 | 1 | |a Tocchetti, Carlo Gabriele |e verfasserin |4 aut | |
| 700 | 1 | |a Yilmaz, Mehmet Birhan |e verfasserin |4 aut | |
| 700 | 1 | |a Vitale, Cristiana |e verfasserin |4 aut | |
| 700 | 1 | |a Volterrani, Maurizio |e verfasserin |4 aut | |
| 700 | 1 | |a von Haehling, Stephan |e verfasserin |4 aut | |
| 700 | 1 | |a Chioncel, Ovidiu |e verfasserin |4 aut | |
| 700 | 1 | |a Coats, Andrew J S |e verfasserin |4 aut | |
| 700 | 1 | |a Rosano, Giuseppe |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of heart failure |d 1999 |g 25(2023), 6 vom: 19. Juni, Seite 776-791 |w (DE-627)NLM106698575 |x 1879-0844 |7 nnns |
| 773 | 1 | 8 | |g volume:25 |g year:2023 |g number:6 |g day:19 |g month:06 |g pages:776-791 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/ejhf.2874 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 25 |j 2023 |e 6 |b 19 |c 06 |h 776-791 | ||